<?xml version='1.0' encoding='utf-8'?>
<document id="27457785"><sentence text="Clarification of the Mechanism of Clopidogrel-Mediated Drug-Drug Interaction in a Clinical Cassette Small-dose Study and Its Prediction Based on In Vitro Information."><entity charOffset="34-45" id="DDI-PubMed.27457785.s1.e0" text="Clopidogrel" /></sentence><sentence text="Clopidogrel is reported to be associated with cerivastatin-induced rhabdomyolysis, and clopidogrel and its metabolites are capable of inhibiting CYP2C8 and OATP 1B1 in vitro"><entity charOffset="0-11" id="DDI-PubMed.27457785.s2.e0" text="Clopidogrel" /><entity charOffset="46-58" id="DDI-PubMed.27457785.s2.e1" text="cerivastatin" /><entity charOffset="87-98" id="DDI-PubMed.27457785.s2.e2" text="clopidogrel" /><pair ddi="false" e1="DDI-PubMed.27457785.s2.e0" e2="DDI-PubMed.27457785.s2.e0" /><pair ddi="false" e1="DDI-PubMed.27457785.s2.e0" e2="DDI-PubMed.27457785.s2.e1" /><pair ddi="false" e1="DDI-PubMed.27457785.s2.e0" e2="DDI-PubMed.27457785.s2.e2" /><pair ddi="false" e1="DDI-PubMed.27457785.s2.e1" e2="DDI-PubMed.27457785.s2.e1" /><pair ddi="false" e1="DDI-PubMed.27457785.s2.e1" e2="DDI-PubMed.27457785.s2.e2" /></sentence><sentence text=" The objective of the present study was to identify the mechanism of clopidogrel-mediated drug-drug interactions (DDIs) on the pharmacokinetics of OATP1B1 and/or CYP2C8 substrates in vivo"><entity charOffset="69-80" id="DDI-PubMed.27457785.s3.e0" text="clopidogrel" /></sentence><sentence text=" A clinical cassette small-dose study using OATPs, CYP2C8, and OATP1B1/CYP2C8 probe drugs (pitavastatin, pioglitazone, and repaglinide, respectively) with or without the coadministration of either 600 mg rifampicin (an inhibitor for OATPs), 200 mg trimethoprim (an inhibitor for CYP2C8), or 300 mg clopidogrel was performed, and the area under the concentration-time curve (AUC) ratios (AUCRs) for probe substrates were predicted using a static model"><entity charOffset="91-103" id="DDI-PubMed.27457785.s4.e0" text="pitavastatin" /><entity charOffset="105-117" id="DDI-PubMed.27457785.s4.e1" text="pioglitazone" /><entity charOffset="123-134" id="DDI-PubMed.27457785.s4.e2" text="repaglinide" /><entity charOffset="204-214" id="DDI-PubMed.27457785.s4.e3" text="rifampicin" /><entity charOffset="233-238" id="DDI-PubMed.27457785.s4.e4" text="OATPs" /><entity charOffset="248-260" id="DDI-PubMed.27457785.s4.e5" text="trimethoprim" /><entity charOffset="298-309" id="DDI-PubMed.27457785.s4.e6" text="clopidogrel" /><entity charOffset="44-54" id="DDI-PubMed.27457785.s4.e7" text="OATPs" /><pair ddi="false" e1="DDI-PubMed.27457785.s4.e7" e2="DDI-PubMed.27457785.s4.e7" /><pair ddi="false" e1="DDI-PubMed.27457785.s4.e7" e2="DDI-PubMed.27457785.s4.e0" /><pair ddi="false" e1="DDI-PubMed.27457785.s4.e7" e2="DDI-PubMed.27457785.s4.e1" /><pair ddi="false" e1="DDI-PubMed.27457785.s4.e7" e2="DDI-PubMed.27457785.s4.e2" /><pair ddi="false" e1="DDI-PubMed.27457785.s4.e7" e2="DDI-PubMed.27457785.s4.e3" /><pair ddi="false" e1="DDI-PubMed.27457785.s4.e7" e2="DDI-PubMed.27457785.s4.e4" /><pair ddi="false" e1="DDI-PubMed.27457785.s4.e7" e2="DDI-PubMed.27457785.s4.e5" /><pair ddi="false" e1="DDI-PubMed.27457785.s4.e7" e2="DDI-PubMed.27457785.s4.e6" /><pair ddi="false" e1="DDI-PubMed.27457785.s4.e0" e2="DDI-PubMed.27457785.s4.e0" /><pair ddi="false" e1="DDI-PubMed.27457785.s4.e0" e2="DDI-PubMed.27457785.s4.e1" /><pair ddi="false" e1="DDI-PubMed.27457785.s4.e0" e2="DDI-PubMed.27457785.s4.e2" /><pair ddi="false" e1="DDI-PubMed.27457785.s4.e0" e2="DDI-PubMed.27457785.s4.e3" /><pair ddi="false" e1="DDI-PubMed.27457785.s4.e0" e2="DDI-PubMed.27457785.s4.e4" /><pair ddi="false" e1="DDI-PubMed.27457785.s4.e0" e2="DDI-PubMed.27457785.s4.e5" /><pair ddi="false" e1="DDI-PubMed.27457785.s4.e0" e2="DDI-PubMed.27457785.s4.e6" /><pair ddi="false" e1="DDI-PubMed.27457785.s4.e1" e2="DDI-PubMed.27457785.s4.e1" /><pair ddi="false" e1="DDI-PubMed.27457785.s4.e1" e2="DDI-PubMed.27457785.s4.e2" /><pair ddi="false" e1="DDI-PubMed.27457785.s4.e1" e2="DDI-PubMed.27457785.s4.e3" /><pair ddi="false" e1="DDI-PubMed.27457785.s4.e1" e2="DDI-PubMed.27457785.s4.e4" /><pair ddi="false" e1="DDI-PubMed.27457785.s4.e1" e2="DDI-PubMed.27457785.s4.e5" /><pair ddi="false" e1="DDI-PubMed.27457785.s4.e1" e2="DDI-PubMed.27457785.s4.e6" /><pair ddi="false" e1="DDI-PubMed.27457785.s4.e2" e2="DDI-PubMed.27457785.s4.e2" /><pair ddi="false" e1="DDI-PubMed.27457785.s4.e2" e2="DDI-PubMed.27457785.s4.e3" /><pair ddi="false" e1="DDI-PubMed.27457785.s4.e2" e2="DDI-PubMed.27457785.s4.e4" /><pair ddi="false" e1="DDI-PubMed.27457785.s4.e2" e2="DDI-PubMed.27457785.s4.e5" /><pair ddi="false" e1="DDI-PubMed.27457785.s4.e2" e2="DDI-PubMed.27457785.s4.e6" /><pair ddi="false" e1="DDI-PubMed.27457785.s4.e3" e2="DDI-PubMed.27457785.s4.e3" /><pair ddi="false" e1="DDI-PubMed.27457785.s4.e3" e2="DDI-PubMed.27457785.s4.e4" /><pair ddi="false" e1="DDI-PubMed.27457785.s4.e3" e2="DDI-PubMed.27457785.s4.e5" /><pair ddi="false" e1="DDI-PubMed.27457785.s4.e3" e2="DDI-PubMed.27457785.s4.e6" /><pair ddi="false" e1="DDI-PubMed.27457785.s4.e4" e2="DDI-PubMed.27457785.s4.e4" /><pair ddi="false" e1="DDI-PubMed.27457785.s4.e4" e2="DDI-PubMed.27457785.s4.e5" /><pair ddi="false" e1="DDI-PubMed.27457785.s4.e4" e2="DDI-PubMed.27457785.s4.e6" /><pair ddi="false" e1="DDI-PubMed.27457785.s4.e5" e2="DDI-PubMed.27457785.s4.e5" /><pair ddi="false" e1="DDI-PubMed.27457785.s4.e5" e2="DDI-PubMed.27457785.s4.e6" /></sentence><sentence text=" Clopidogrel increased the AUC of pioglitazone (2"><entity charOffset="1-12" id="DDI-PubMed.27457785.s5.e0" text="Clopidogrel" /><entity charOffset="34-46" id="DDI-PubMed.27457785.s5.e1" text="pioglitazone" /><pair ddi="false" e1="DDI-PubMed.27457785.s5.e0" e2="DDI-PubMed.27457785.s5.e0" /><pair ddi="false" e1="DDI-PubMed.27457785.s5.e0" e2="DDI-PubMed.27457785.s5.e1" /></sentence><sentence text="0-fold) and repaglinide (3"><entity charOffset="12-23" id="DDI-PubMed.27457785.s6.e0" text="repaglinide" /></sentence><sentence text="1-fold) but did not significantly change the AUC of pitavastatin (1"><entity charOffset="52-64" id="DDI-PubMed.27457785.s7.e0" text="pitavastatin" /></sentence><sentence text="1-fold)" /><sentence text=" In addition, the AUC of pioglitazone M4, a CYP2C8-mediated metabolite of pioglitazone, was reduced to 70% of the control by coadministration of clopidogrel"><entity charOffset="25-37" id="DDI-PubMed.27457785.s9.e0" text="pioglitazone" /><entity charOffset="74-86" id="DDI-PubMed.27457785.s9.e1" text="pioglitazone" /><entity charOffset="145-156" id="DDI-PubMed.27457785.s9.e2" text="clopidogrel" /><pair ddi="false" e1="DDI-PubMed.27457785.s9.e0" e2="DDI-PubMed.27457785.s9.e0" /><pair ddi="false" e1="DDI-PubMed.27457785.s9.e0" e2="DDI-PubMed.27457785.s9.e1" /><pair ddi="false" e1="DDI-PubMed.27457785.s9.e0" e2="DDI-PubMed.27457785.s9.e2" /><pair ddi="false" e1="DDI-PubMed.27457785.s9.e1" e2="DDI-PubMed.27457785.s9.e1" /><pair ddi="false" e1="DDI-PubMed.27457785.s9.e1" e2="DDI-PubMed.27457785.s9.e2" /></sentence><sentence text=" The predicted AUCRs using the mechanism-based inhibition of CYP2C8 by clopidogrel acyl-β-glucuronide were similar to the observed AUCRs, and the predicted AUCR (1"><entity charOffset="71-101" id="DDI-PubMed.27457785.s10.e0" text="clopidogrel acyl-β-glucuronide" /></sentence><sentence text="1) of repaglinide using only the inhibition of OATP1B1 did not reach the observed AUCR (3"><entity charOffset="6-17" id="DDI-PubMed.27457785.s11.e0" text="repaglinide" /></sentence><sentence text="1)" /><sentence text=" In conclusion, a single 300 mg of clopidogrel mainly inhibits CYP2C8-mediated metabolism by clopidogrel acyl-β-glucuronide, but its effect on the pharmacokinetics of OATP1B1 substrates is negligible"><entity charOffset="35-46" id="DDI-PubMed.27457785.s13.e0" text="clopidogrel" /><entity charOffset="93-123" id="DDI-PubMed.27457785.s13.e1" text="clopidogrel acyl-β-glucuronide" /><pair ddi="false" e1="DDI-PubMed.27457785.s13.e0" e2="DDI-PubMed.27457785.s13.e0" /><pair ddi="false" e1="DDI-PubMed.27457785.s13.e0" e2="DDI-PubMed.27457785.s13.e1" /></sentence><sentence text=" Clopidogrel is expected to have an effect not only on CYP2C8 substrates, but also dual CYP2C8/OATP1B1 substrates as seen in the case of repaglinide"><entity charOffset="1-12" id="DDI-PubMed.27457785.s14.e0" text="Clopidogrel" /><entity charOffset="137-148" id="DDI-PubMed.27457785.s14.e1" text="repaglinide" /><pair ddi="false" e1="DDI-PubMed.27457785.s14.e0" e2="DDI-PubMed.27457785.s14.e0" /><pair ddi="false" e1="DDI-PubMed.27457785.s14.e0" e2="DDI-PubMed.27457785.s14.e1" /></sentence><sentence text="" /></document>